Advertisement
Podcast

Peter Libby, MD, on Clonal Hematopoiesis of Indeterminate Potential and Atherosclerosis

03/04/2020

 

In this podcast, Peter Libby, MD, gives an overview of clonal hematopoiesis of indeterminate potential, how it relates to cardiovascular medicine, and why it should be on your radar.

Peter Libby, MD, is a cardiology specialist at Brigham and Women’s Hospital and the Mallinckrodt Professor of Medicine at Harvard Medical School in Boston Massachusetts. 

Additional Resources:

 

Note: Dr Libby does not endorse any products or services advertised on this page.

Related Content

Diabetes
Diabetes
Alexander Turchin, MD, on Predictors of Declining Insulin Therapy for Type 2 Diabetes
03/25/2020
Dr Turchin discusses the findings of his recent study, which identified predictors and consequences of declining insulin therapy among patients with type 2 diabetes. He also explains how endocrinologists...
03/25/2020
Multiple Sclerosis
Multiple Sclerosis
Murali Ramanathan, PhD, on How Lipid Management Affects MS Outcomes
04/21/2020
He discusses his latest research on how managing lipid levels with the Wahls diet and other integrative interventions affects fatigue related to multiple sclerosis.
04/21/2020
Gastroenterology
Gastroenterology
Sunanda Kane, MD, Managing Severe Ulcerative Colitis: Updated Guidelines Are Needed
11/26/2018
Dr Sunanda Kane, president of the American College of Gastroenterology, discusses current guidelines for managing severe ulcerative colitis, controversies surrounding rescue treatment, and more.
11/26/2018
RA Excellence Forum
RA Excellence Forum
George Karpouzas, MD, on the Biomarkers for Predicting Coronary Atherosclerosis in RA
05/28/2020
Dr Karpouzas talks about his research on highly sensitive cardiac troponin-I and IgA antibodies against β-2 glycoprotein 1 in the setting of coronary atherosclerosis among patients with rheumatoid...
05/28/2020
Cardiovascular Diseases
Cardiovascular Diseases
Expert Conversations: SLGT2 Inhibitors for HF, Cardio-Renal Connection
06/14/2018
Dr Seth Baum interviews Dr Mikhail Kosiborod about clinical trial data surrounding the possible mechanisms of action of SLGT2 inhibitors for heart failure, as well as the cardio-renal connection.
06/14/2018